Strategic treatment optimization for HCV (STOPHCV1): a randomised controlled trial of ultrashort duration therapy for chronic hepatitis C [version 2; peer review: 2 approved]

Strategic treatment optimization for HCV (STOPHCV1): a randomised controlled trial of ultrashort duration therapy for chronic hepatitis C [version 2; peer review: 2 approved]

Background: The World Health Organization (WHO) has identified the need for a better understanding of which patients with hepatitis C virus (HCV) can be cured with ultrashort course HCV therapy. Methods: A total of 202 individuals with chronic HCV were randomised to fixed-duration shortened therapy...

Full description

Bibliographic Details
Main Authors: Graham S. Cooke, Sarah Pett, Leanne McCabe, Chris Jones, Richard Gilson, Sumita Verma, Stephen D. Ryder, Jane D. Collier, Stephen T. Barclay, Aftab Ala, Sanjay Bhagani, Mark Nelson, Chinlye Ch'Ng, Ben Stone, Martin Wiselka, Daniel Forton, Stuart McPherson, Rachel Halford, Dung Nguyen, David Smith, Azim Ansari, Emily Dennis, Fleur Hudson, Eleanor J. Barnes, Ann Sarah Walker
Format: Article
Language:English
Published: Wellcome 2021-07-01
Series:Wellcome Open Research
Online Access:https://wellcomeopenresearch.org/articles/6-93/v2

Internet

https://wellcomeopenresearch.org/articles/6-93/v2

Similar Items